
MIZUHO MEDY CO.,LTD.
4595 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 鳥栖市藤木町5番地の4
- Website:
- https://www.mizuho-m.co.jp/en/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
MIZUHO MEDY Co., Ltd., based in Tosu, Saga, Japan, specializes in in vitro diagnostics, offering a comprehensive range of innovative products. The company is renowned for its advanced nucleic acid amplification tests and rapid immunoassays catering to clinical, research, and agricultural applications. Notable offerings include the Smart Gene® series and the Quick Chaser line, which addresses various pathogens, including SARS-CoV-2 and RSV. Committed to quality, MIZUHO MEDY has achieved ISO 13485 certification for its operations, ensuring adherence to stringent quality management standards. With a focus on technological advancement, the company actively participates in international exhibitions, showcasing its commitment to healthcare innovation and improving diagnostic solutions.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
2025-04-02 06:17 |
Inside Information Statement
臨時報告書
|
Japanese | 25.9 KB | |
2025-03-31 03:44 |
Internal Control over Financial Reporting
内部統制報告書-第48期(2024/01/01-2024/12/31)
|
Japanese | 22.5 KB | |
2025-03-31 03:41 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
2025-03-31 03:37 |
Annual Report
有価証券報告書-第48期(2024/01/01-2024/12/31)
|
Japanese | 931.6 KB | |
2024-08-09 06:11 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
2024-08-09 06:09 |
Interim Report
半期報告書-第48期(2024/01/01-2024/12/31)
|
Japanese | 209.8 KB | |
2024-05-10 06:07 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
2024-05-10 06:06 |
Quarterly Report
四半期報告書-第48期第1四半期(2024/01/01-2024/03/31)
|
Japanese | 169.5 KB | |
2024-04-01 09:48 |
Inside Information Statement
臨時報告書
|
Japanese | 21.6 KB | |
2024-03-29 02:02 |
Internal Control over Financial Reporting
内部統制報告書-第47期(2023/01/01-2023/12/31)
|
Japanese | 22.5 KB | |
2024-03-29 01:59 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
2024-03-29 01:56 |
Annual Report
有価証券報告書-第47期(2023/01/01-2023/12/31)
|
Japanese | 967.0 KB |
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
No insider transactions recorded for this company. |
Peer Companies
Company | Country | Ticker | View | |
---|---|---|---|---|
![]() |
EQL Pharma AB | Sweden | EQL | |
E.S. Australia Israel Holdings LTD | Israel | AUIS | ||
![]() |
EuroAPI | France | EAPI | |
![]() |
Eurofins-Cerep | France | ALECR | |
![]() |
EUROPEAN GREEN TRANSITION PLC | United Kingdom | EGT | |
|
Evolear AB | Sweden | EVOL | |
![]() |
Faes Farma S.A. | Spain | FAE | |
|
Fagron N.V. | Belgium | FAGR | |
|
Farmak | Ukraine | FARM | |
![]() |
Farmsintez ao | Russian Federation | LIFE |